World Journal of Pharmaceutical and Life Sciences
WJPLS
www.wjpls.org
SJIF Impact Factor: 7.409

A COMPREHENSIVE REVIEW OF INHALATION INSULIN: EVALUATING ITS EFFICACY, SAFETY PROFILE, MECHANISTIC INSIGHTS, CLINICAL APPLICATIONS, AND POTENTIAL TO TRANSFORM DIABETES MANAGEMENT AND PATIENT ADHERENCE IN THE CONTEXT OF EVOLVING THERAPEUTIC STRATEGIES

Agilandeswari Devarajan[1], Sagar[2], Pinnu Sathish Kumar[3], Kanika[4], Anil Kumar[5], Arpan Dutta[6], Manoj Kumar Katual[7] , Yash Srivastav[8] and Uriti Sri Venkatesh[9]*

[1]Professor, Department of Pharmaceutics, MVM College of Pharmacy, Bangalore. Karnataka, India.
[2]Assistant Professor, Department of Pharmaceuticals Science, Chaudhary Devi Lal University,Sirsa, Haryana, India.
[3]Associate Professor, Department of Pharmacology, MVM College of Pharmacy, Bangalore. Karnataka, India.
[4]Part Time Teacher, Department of Pharmaceuticals Science, Chaudhary Devi Lal University,Sirsa, Haryana, India.
[5]Head & Assistant Professor, Department of Chemistry (PG), Sahibganj College Sahibganj, Jharkhand, India.
[6]Research Assistant, Insilico and Drug Research,Drug Chemistry Research Centre, India.
[7]Associate Professor & Dean, Faculty of Pharmacy, Guru Kashi University, Bhatinda, Punjab, India.
[8]Assistant Professor, Department of Pharmacy, Shri Venkateshwara University, Gajraula, Uttar Pradesh, India.
[*9]Associate Professor, Department of Pharmacology, Sri Sivani college of Pharmacy, Srikakulam, Andhra Pradesh, India.

***Corresponding Author: Uriti Sri Venkatesh**
Associate Professor, Department of Pharmacology, Sri Sivani college of Pharmacy, Srikakulam, Andhra Pradesh, India.

Article Received on 20/01/2025 **Article Revised on 10/02/2025** **Article Accepted on 01/03/2025**

ABSTRACT
Diabetes mellitus (DM) is a chronic metabolic disorder affecting millions worldwide, requiring effective glycemic control to prevent complications. Insulin therapy is the cornerstone of diabetes management, yet traditional subcutaneous injections pose challenges related to patient adherence, injection discomfort, and delayed pharmacokinetics. Inhaled insulin emerges as a promising alternative, offering a non-invasive, rapid-acting approach that mimics endogenous insulin secretion more closely than subcutaneous administration. Despite its potential, early formulations like Exubera faced market failure due to bulky device design and safety concerns. However, newer advancements, particularly Afrezza, have demonstrated improved bioavailability, better patient adherence, and faster onset of action. This review explores the mechanism of action, pharmacokinetics, clinical efficacy, safety profile, delivery technologies, regulatory challenges, and economic considerations of inhaled insulin. Furthermore, it discusses patient adherence trends, emerging AI-driven insulin monitoring systems, and future perspectives in diabetes management. Although inhaled insulin shows promise in improving patient compliance and glycemic control, challenges such as cost-effectiveness, long-term pulmonary safety, and insurance coverage remain critical barriers. Advancements in nanoparticle-based insulin formulations, smart inhalers, and personalized medicine approaches may further enhance the feasibility and adoption of inhaled insulin in clinical practice.

KEYWORDS: Diabetes mellitus, Inhaled insulin, Afrezza, Exubera, Pulmonary insulin delivery, Pharmacokinetics, Patient adherence, Smart inhalers, Regulatory challenges, Nanoparticle insulin formulations.

1. INTRODUCTION

1.1 Overview of Diabetes Mellitus and the Need for Alternative Insulin Delivery Methods

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia due to insulin deficiency, insulin resistance, or both. The global prevalence of diabetes has increased significantly, with an estimated 537 million adults affected in 2021, a number projected to reach 783 million by 2045 (International Diabetes Federation [IDF], 2021). The two primary forms of diabetes, type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), require effective glycemic control to prevent long-term complications such as nephropathy, neuropathy, retinopathy, and cardiovascular diseases (American Diabetes Association [ADA], 2023).

Insulin therapy remains the cornerstone of diabetes management, particularly for patients with T1DM and those with advanced T2DM who no longer achieve adequate glycemic control with oral antihyperglycemic agents (Davies et al., 2018). However, conventional subcutaneous insulin delivery presents significant challenges, including the discomfort of multiple daily injections, injection site reactions, the risk of hypoglycemia, and poor patient adherence (Grunberger, 2020). Given these limitations, there is a growing interest in non-invasive insulin delivery systems that can enhance patient compliance while maintaining effective glucose regulation.

1.2 Historical Perspective on Insulin Therapy and Limitations of Subcutaneous Administration

The discovery of insulin in 1921 by Banting and Best revolutionized diabetes management, transforming a previously fatal condition into a manageable chronic disease (Bliss, 1982). Early insulin formulations were derived from animal sources, but advancements led to the development of recombinant human insulin and, subsequently, insulin analogs with improved pharmacokinetic profiles (Hirsch, 2005). Despite these innovations, subcutaneous administration remains the primary mode of insulin delivery, requiring either multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) via insulin pumps.

The reliance on injections poses barriers to adherence, particularly among individuals with needle phobia or those experiencing injection-related discomfort (Peyrot et al., 2012). Additionally, subcutaneous insulin delivery may not mimic the physiological pulsatile secretion of endogenous insulin, leading to delayed postprandial glucose control and increased risk of nocturnal hypoglycemia (Owens et al., 2020). These challenges have driven research efforts to explore alternative insulin delivery routes, including transdermal, oral, and pulmonary systems.

1.3 Introduction to Inhalation Insulin as a Novel Delivery System

Inhalation insulin represents a promising alternative to subcutaneous injections, offering a needle-free approach that improves patient convenience and adherence. The concept of pulmonary insulin delivery is based on the extensive surface area and high vascularization of the alveoli, which allow for rapid systemic absorption (Patton & Byron, 2007). This method provides a more physiological insulin kinetics profile, closely resembling endogenous insulin secretion, particularly in controlling postprandial glucose levels (Rosenstock et al., 2015).

The first inhaled insulin product, Exubera, was introduced to the market in 2006 but was withdrawn due to poor patient acceptance and commercial failure (Barnett, 2007). However, subsequent advancements led to the development of Afrezza, a rapid-acting inhaled insulin approved by the FDA in 2014, which has shown improved pharmacokinetics and patient satisfaction (Heinemann, 2019). Despite its advantages, concerns regarding pulmonary safety, dosing precision, and long-term effects remain topics of ongoing investigation.

1.4 Aim and Scope of review

This review aims to provide a comprehensive evaluation of inhaled insulin as a novel therapeutic approach in diabetes management. The primary objective is to assess its efficacy, safety, pharmacokinetics, and clinical utility compared to traditional subcutaneous insulin delivery. By analyzing current advancements in formulation technologies, inhaler devices, and patient adherence patterns, this review seeks to determine the potential of inhaled insulin to transform diabetes care. It also explores regulatory challenges, market adoption trends, and cost-effectiveness considerations, shedding light on the factors that influence its accessibility and widespread acceptance.

The scope of this review encompasses the scientific, clinical, and economic aspects of inhaled insulin therapy. It covers the historical development of inhaled insulin, detailing the rise and fall of Exubera and the subsequent success of Afrezza. Additionally, it delves into the mechanisms of pulmonary insulin absorption, bioavailability, and metabolism, along with emerging innovations such as nanoparticle-based insulin formulations and AI-driven insulin dosing technologies. The impact of inhaled insulin on patient adherence, quality of life, and glycemic control is critically analyzed, offering insights into its real-world application. Furthermore, the review discusses the regulatory landscape, insurance coverage issues, and cost-related barriers that influence market penetration.

By synthesizing the latest research, clinical trials, and technological advancements, this review aims to provide a holistic understanding of inhaled insulin's potential to revolutionize diabetes management. It also identifies gaps in current knowledge and future directions for optimizing inhaled insulin formulations, improving device design, and addressing concerns regarding long-term pulmonary safety and accessibility.

2. Mechanism of Action and Pharmacokinetics of Inhalation Insulin

Inhalation insulin represents a novel approach to insulin delivery that leverages the highly vascularized pulmonary route to achieve rapid systemic absorption. Unlike subcutaneous insulin, which requires diffusion from the injection site into the bloodstream, inhaled insulin is absorbed directly into the alveolar capillaries, allowing for faster onset and shorter duration of action. This section explores the key pharmacokinetic properties of inhalation insulin, including its absorption, distribution, metabolism, and excretion, along with the factors influencing its pulmonary uptake.

2.1 Absorption and Bioavailability Through the Pulmonary Route

The human lung offers an extensive surface area (~140 m^2) and a thin alveolar-capillary barrier (~0.2 µm), making it an ideal site for systemic drug delivery (Patton & Byron, 2007). Insulin delivered via the pulmonary route is absorbed by passive diffusion through the alveolar epithelium into the systemic circulation, bypassing the first-pass hepatic metabolism seen with oral insulin formulations (Cefalu, 2004).

The bioavailability of inhaled insulin is estimated to be 10–30% of a subcutaneous dose, with variations depending on patient-specific lung physiology and inhalation technique (Hochhaus et al., 2015). Pulmonary insulin absorption is influenced by the particle size, lung deposition efficiency, and pulmonary clearance mechanisms. For effective systemic delivery, insulin particles must reach the deep lung alveoli, requiring an aerodynamic diameter of 1–5 µm (Dunbar et al., 2002). Larger particles (>5 µm) tend to deposit in the upper airways, leading to reduced absorption and increased oropharyngeal clearance.

Table 1: Comparison of Inhaled vs. Subcutaneous Insulin Bioavailability

Parameter	Inhaled Insulin	Subcutaneous Insulin
Bioavailability (%)	10–30%	~100%
Onset of action (min)	12–15	30–60
Peak concentration (min)	30–60	90–120
Duration of action (hours)	2–3	4–6
First-pass metabolism	No	No
Route of elimination	Pulmonary clearance	Renal & hepatic clearance

Sources: Patton & Byron, 2007; Hochhaus et al., 2015; Heinemann, 2019

2.2 Comparison with Subcutaneous Insulin (Onset, Peak, and Duration of Action)

One of the key advantages of inhaled insulin is its faster onset and shorter duration of action, which more closely mimics endogenous insulin secretion in response to meals. Traditional rapid-acting subcutaneous insulin analogs, such as insulin lispro and insulin aspart, have an onset of 30–60 minutes and peak at 90–120 minutes, whereas inhaled insulin demonstrates a significantly faster onset of 12–15 minutes and peaks within 30–60 minutes (Rosenstock et al., 2015).

This rapid absorption makes inhaled insulin particularly beneficial for postprandial glucose control, reducing the risk of late postprandial hypoglycemia, which is commonly associated with subcutaneous insulin injections (Heinemann, 2019). However, due to its shorter duration of action (~2–3 hours), inhaled insulin requires more frequent dosing to maintain glycemic stability throughout the day.

2.3 Factors Affecting Pulmonary Absorption

Several factors influence the efficiency of inhaled insulin absorption, including particle size, lung deposition, and bioengineering aspects of the inhaler device.

2.3.1 Particle Size and Lung Deposition

- Optimal inhaled insulin particles must have an aerodynamic diameter of 1–5 µm to ensure effective alveolar deposition (Dunbar et al., 2002).
- Particles >5 µm tend to deposit in the oropharyngeal region, leading to swallowing and reduced bioavailability.
- Particles <1 µm are often exhaled before deposition occurs.

2.3.2 Inhalation Technique and Device Engineering

- **Deep inhalation** with sufficient inspiratory effort ensures better drug delivery to the lungs.
- **Pulmonary function status** (e.g., presence of asthma, COPD) affects insulin absorption.
- **Device type** (e.g., dry powder inhalers vs. nebulizers) influences deposition efficiency.

Table 2: Factors Affecting Pulmonary Insulin Absorption.

Factor	Impact on Absorption	Examples
Particle Size (µm)	1–5 µm optimal for alveolar deposition	Exubera (5.5 µm), Afrezza (2–3 µm)
Inspiratory Flow Rate	Higher flow enhances deep lung deposition	≥ 30 L/min recommended
Pulmonary Health	Reduced absorption in lung diseases	Asthma, COPD
Device Efficiency	Determines lung deposition	DPI vs. nebulizers

Sources: Dunbar et al., 2002; Patton & Byron, 2007; Heinemann, 2019

2.4 Metabolism and Clearance of Inhalation Insulin

Once absorbed into the systemic circulation, inhaled insulin follows the same metabolic pathways as endogenous insulin. The liver and kidneys primarily metabolize insulin through proteolytic degradation, with hepatic metabolism accounting for approximately 50–60% of insulin clearance (Hochhaus et al., 2015).

2.4.1 Pulmonary Clearance Mechanisms

- A small fraction of inhaled insulin is cleared by mucociliary transport, leading to gastrointestinal degradation.
- Alveolar macrophages play a role in insulin uptake and degradation, which may contribute to the immunogenic concerns associated with inhaled insulin (Barnett, 2007).
- The half-life of inhaled insulin is shorter (~1 hour) compared to subcutaneous insulin (~4 hours), necessitating frequent dosing for sustained glucose control (Rosenstock et al., 2015).

3. Clinical Efficacy and Safety Profile of Inhalation Insulin

The clinical efficacy and safety profile of inhaled insulin are critical considerations for its adoption in diabetes management. This section examines key clinical trials, compares inhaled insulin with subcutaneous formulations, evaluates its impact on glycemic control, and explores potential safety concerns such as pulmonary effects and long-term risks.

3.1 Evaluation of Clinical Trials on Inhaled Insulin

Several clinical trials have assessed the efficacy and safety of inhaled insulin in patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). The pivotal studies have focused on comparing inhaled insulin with rapid-acting subcutaneous insulin in terms of HbA1c reduction, postprandial glucose control, and patient adherence.

3.1.1 Key Clinical Trials and Findings

Exubera Trials (2006)

- Exubera, the first inhaled insulin approved by the FDA, was evaluated in multiple phase III trials.
- Studies demonstrated comparable HbA1c reduction (~0.7–1.0%) to subcutaneous insulin but highlighted higher patient satisfaction due to the non-invasive delivery method (Skyler et al., 2005).
- However, concerns regarding pulmonary function decline and poor device acceptability led to its market withdrawal in 2007 (Barnett, 2007).

Afrezza Trials (2014–Present)

- Afrezza, a rapid-acting inhaled insulin, was approved in 2014 and has undergone multiple phase III studies.
- Clinical trials demonstrated faster onset and lower postprandial glucose excursions compared to subcutaneous insulin aspart (Rosenstock et al., 2015).
- HbA1c reduction in T1DM patients was non-inferior to subcutaneous rapid-acting insulin, with lower hypoglycemia rates (Heinemann, 2019).
- In T2DM, inhaled insulin was effective as an adjunct to oral therapy, improving postprandial glucose control (Bode et al., 2015).

Table 3: Summary of Key Clinical Trials on Inhaled Insulin.

Study	Insulin Type	Patient Population	HbA1c Change (%)	Key Findings
Skyler et al., 2005	Exubera	T1DM, T2DM	-0.7 to -1.0	Effective but led to mild pulmonary function decline
Rosenstock et al., 2015	Afrezza	T1DM	-0.6 to -0.8	Faster onset, lower postprandial glucose, fewer hypoglycemic events
Bode et al., 2015	Afrezza	T2DM (on oral drugs)	-0.4 to -0.6	Improved postprandial glucose, good patient adherence

Sources: Skyler et al., 2005; Barnett, 2007; Rosenstock et al., 2015; Heinemann, 2019; Bode et al., 2015.

3.2 Comparison with Subcutaneous Insulin in Glycemic Control

3.2.1 HbA1c Reduction and Postprandial Glucose Control

- Inhaled insulin has shown comparable HbA1c reductions to subcutaneous rapid-acting insulin but provides better postprandial glucose control due to its faster absorption (Rosenstock et al., 2015).
- The shorter duration of action helps reduce late postprandial hypoglycemia, a common issue with injected insulin (Heinemann, 2019).

3.2.2 Risk of Hypoglycemia

- Compared to subcutaneous insulin, inhaled insulin demonstrates lower overall hypoglycemia rates, particularly in type 2 diabetes (Bode et al., 2015).
- The shorter duration of action prevents prolonged insulin exposure, reducing nocturnal hypoglycemia risk (Rosenstock et al., 2015).

3.3 Safety Concerns and Adverse Effects

While inhaled insulin provides several advantages, safety concerns remain, particularly regarding pulmonary function, respiratory irritation, and potential long-term effects.

3.3.1 Pulmonary Function and Respiratory Effects

- A slight decline in forced expiratory volume (FEV1) has been observed in long-term studies, although it is generally reversible upon discontinuation (Barnett, 2007).
- Cough is the most common side effect, occurring in 20–30% of users, often transient and dose-dependent (Heinemann, 2019).

3.3.2 Long-Term Safety Considerations

- Concerns exist about insulin accumulation in lung tissues, but no significant increase in pulmonary fibrosis or malignancy has been reported in clinical studies (Rosenstock et al., 2015).

- Smokers and individuals with lung diseases (e.g., COPD, asthma) are not recommended for inhaled insulin due to altered absorption kinetics and safety concerns (Bode et al., 2015).

4. Formulations and Delivery Systems of Inhalation Insulin

The development of inhalation insulin represents a major advancement in diabetes therapy by offering a non-invasive alternative to subcutaneous injections. This section explores the available formulations, technological advancements in dry powder and aerosol-based insulin delivery, different inhaler device designs, and important stability and storage considerations for ensuring the efficacy of inhaled insulin.

4.1 Overview of Available Inhalation Insulin Formulations

Several inhaled insulin products have been developed over the years, though only a few have gained regulatory approval and clinical adoption. The two most notable formulations are **Exubera** (now discontinued) and **Afrezza**, which remains the only FDA-approved inhaled insulin on the market.

4.1.1 Exubera (Discontinued)

- Developed by Pfizer and approved by the FDA in 2006.
- Delivered human recombinant insulin in a dry powder formulation using a bulky inhaler device (Skyler et al., 2007).
- Withdrawn from the market in 2007 due to poor patient acceptance, large device size, and financial losses (Barnett, 2007).
- Concerns over pulmonary safety and long-term effects further contributed to its discontinuation.

4.1.2 Afrezza (Currently Available)

- Developed by MannKind Corporation and approved by the FDA in 2014.
- Uses a Technosphere® insulin formulation, where insulin is encapsulated in fumaryl diketopiperazine microparticles, optimizing pulmonary deposition (Heinemann, 2019).
- Offers **ultra-rapid onset**, making it suitable for **postprandial glucose control** (Bashan et al., 2021).
- Comes with a **compact, user-friendly inhaler** (Dreamboat®) that **improves portability and ease of use** compared to Exubera.

Table 4: Comparison of Exubera and Afrezza.

Feature	Exubera (Discontinued)	Afrezza (Current)
Approval Year	2006	2014
Company	Pfizer	MannKind Corporation
Formulation	Dry powder recombinant insulin	Technosphere® Insulin
Device	Bulky inhaler	Compact inhaler (Dreamboat®)
Onset of Action	~45 min	~12-15 min (ultra-rapid)
Market Status	Discontinued (2007)	Currently available

Sources: Barnett, 2007; Heinemann, 2019; Bashan et al., 2021.

4.2 Advances in Dry Powder and Aerosol-Based Insulin Delivery Technologies

The success of inhaled insulin largely depends on particle engineering, aerodynamic properties, and bioavailability enhancement.

4.2.1 Dry Powder Insulin Technologies

- Dry powder insulin formulations are engineered to optimize lung deposition, typically within 1–5 µm particle size range (Patton & Byron, 2007).
- Technologies like Technosphere® insulin use fumaryl diketopiperazine microparticles, ensuring efficient deep lung absorption (Hochhaus & Liang, 2021).
- Spray-drying and freeze-drying techniques are used to improve stability and dispersibility (Rosenstock et al., 2015).

4.2.2 Aerosolized Insulin Delivery

- Uses liquid insulin formulations in nebulizers or pressurized metered-dose inhalers (pMDIs).
- Provides controlled droplet size but has lower efficiency due to oropharyngeal deposition (Brunner et al., 2020).
- Challenges: Requires higher insulin doses due to lower lung absorption efficiency compared to dry powders.

Table 5: Comparison of Dry Powder vs. Aerosolized Insulin Delivery.

Feature	Dry Powder Insulin	Aerosolized Insulin
Formulation	Powdered insulin microparticles	Liquid insulin aerosol
Delivery Device	Inhalers (Afrezza, Exubera)	Nebulizers, pMDIs
Particle Size	1-5 µm (ideal for lung deposition)	1-10 µm (less efficient)
Absorption Efficiency	High (deep lung penetration)	Moderate (oropharyngeal loss)
Commercial Availability	Afrezza (Technosphere®)	Under research and development

Sources: Patton & Byron, 2007; Rosenstock et al., 2015; Brunner et al., 2020; Hochhaus & Liang, 2021.

4.3 Device Designs and Mechanisms (Inhalers and Nebulizers)

Efficient pulmonary drug delivery requires **specialized devices** that generate **optimal particle size distribution** for lung deposition.

4.3.1 Dry Powder Inhalers (DPI)

- Used for Afrezza and Exubera formulations.
- Work by dispersing insulin powder into inhalable microparticles.
- Compact and breath-actuated, requiring no external power source.
- Limitation: Patient inhalation effort must be adequate for proper dose delivery.

4.3.2 Metered-Dose Inhalers (MDI)

- Utilize propellant-driven aerosolization of insulin formulations.
- Offer precise dosing, but absorption efficiency remains lower than DPIs.

4.3.3 Nebulizers

- Convert liquid insulin into a fine mist for inhalation.
- Provide continuous drug delivery, suitable for hospital settings.
- Limitations: Less convenient for daily use due to device size and maintenance requirements.

4.4 Stability and Storage Considerations

4.4.1 Factors Affecting Stability

- Humidity and Moisture: Dry powder insulin is sensitive to humidity, requiring sealed packaging (Patton et al., 2021).
- Temperature Sensitivity: Needs storage at controlled temperatures (2-8°C) to maintain potency (Brunner et al., 2020).
- Oxidation and Degradation: Avoid direct light and air exposure to prevent insulin denaturation.

4.4.2 Shelf-Life Considerations

- Afrezza cartridges have a shelf life of ~2 years when stored properly.
- Once opened, the insulin powder must be used within 3-10 days to maintain efficacy (Hochhaus & Liang, 2021).
- Formulation advancements, including stabilizing excipients, aim to extend storage stability at room temperature.

The success of inhaled insulin delivery depends on formulation optimization, device engineering, and stability management. While Afrezza has addressed some of Exubera's limitations, further improvements in nanoparticle-based carriers, smart inhaler integration, and long-term safety assessments are required to expand the clinical utility of inhaled insulin.

5. Patient Adherence, Quality of Life, and Acceptance of Inhalation Insulin

The introduction of inhaled insulin offers a non-invasive alternative to traditional subcutaneous insulin injections, significantly impacting patient adherence, quality of life, and overall treatment acceptance. This section explores factors influencing patient preferences, real-world adherence trends, and psychological and practical aspects of inhalation insulin use.

5.1 Factors Influencing Patient Adherence

Adherence to insulin therapy is crucial for optimal glycemic control in diabetes management. Several factors influence patient adherence, particularly the transition from injections to inhalation insulin:

5.1.1 Convenience and Ease of Use

- Many patients with diabetes experience "injection fatigue," leading to poor adherence (Polonsky & Henry, 2016).
- Inhaled insulin eliminates the need for multiple daily injections, enhancing convenience, particularly for postprandial insulin dosing (Barnett, 2007).

5.1.2 Needle Phobia and Psychological Barriers

- Approximately 25% of insulin users report needle anxiety, leading to dose-skipping or reluctance to initiate insulin therapy (Hood et al., 2018).
- Inhaled insulin reduces psychological barriers associated with injections, improving patient satisfaction and willingness to continue treatment (Rosenstock et al., 2015).

5.1.3 Discreet Administration and Social Acceptance

- Inhaled insulin is more discreet than injections, allowing patients to administer insulin in social or professional settings without stigma (Heinemann, 2019).
- Studies suggest that patients prefer inhaled insulin due to reduced embarrassment and increased treatment flexibility (Bode et al., 2015).

Table 6: Patient Preferences for Inhaled Insulin vs. Subcutaneous Insulin

Factor	Inhaled Insulin	Subcutaneous Insulin
Ease of Administration	High	Moderate to Low
Needle Phobia Reduction	Yes	No
Social Acceptance	High	Moderate
Postprandial Convenience	High	Moderate
Risk of Hypoglycemia	Lower	Higher

Sources: Polonsky & Henry, 2016; Rosenstock et al., 2015; Heinemann, 2019.

5.2 Impact on Quality of Life

5.2.1 Patient-Reported Outcomes and Satisfaction

- Studies evaluating patient-reported outcomes indicate that inhaled insulin improves treatment satisfaction and quality of life (Bode et al., 2015).
- Greater flexibility in dosing and less anxiety about insulin therapy contribute to improved psychological well-being (Polonsky & Henry, 2016).

5.2.2 Effect on Daily Lifestyle and Meal Planning

- Inhaled insulin provides a faster onset and shorter duration, making it ideal for spontaneous meals (Heinemann, 2019).
- Patients report fewer restrictions on food timing, leading to better diet adherence and lifestyle satisfaction (Bode et al., 2015).

5.3 Real-World Adherence and Challenges

Despite its advantages, **real-world adherence** to inhaled insulin has been mixed due to certain limitations:

5.3.1 Device-Related Challenges

- Some patients find inhalation devices bulky or difficult to use, affecting adherence (Barnett, 2007).
- Proper inhalation technique is required for effective absorption, posing challenges for some elderly or respiratory-compromised patients (Bode et al., 2015).

5.3.2 Cost and Insurance Coverage

- Inhaled insulin is more expensive than subcutaneous insulin, and insurance coverage varies (Heinemann, 2019).
- Cost concerns may limit long-term adherence, particularly in low-income populations (Polonsky & Henry, 2016).

5.3.3 Pulmonary Safety Concerns

- Some patients and healthcare providers are cautious due to long-term pulmonary safety concerns, despite clinical evidence suggesting minimal risk (Rosenstock et al., 2015).

6. Future Perspectives and Potential for Transforming Diabetes Management

The development and adoption of inhaled insulin have marked a significant milestone in diabetes care. While challenges remain, ongoing advancements in formulation technology, device engineering, and patient-centered care are expected to improve its clinical utility. This section explores emerging innovations, ongoing research, potential regulatory advancements, and the broader implications of inhaled insulin in the evolving landscape of diabetes therapy.

6.1 Advancements in Inhaled Insulin Formulations

Innovations in particle engineering, excipient technology, and bioavailability enhancement are key to improving the efficacy and stability of inhaled insulin.

6.1.1 Nanoparticle-Based Insulin Formulations

- Nano-carriers such as liposomes, polymeric nanoparticles, and lipid-based carriers are being explored to enhance pulmonary absorption (Zhou et al., 2020).
- These formulations improve stability, bioavailability, and targeted delivery to alveolar regions (Kiparissides et al., 2018).

6.1.2 Dry Powder Optimization for Enhanced Pulmonary Deposition

- Particle size reduction (1-5 µm) enhances lung deposition, leading to better absorption and glycemic control (Hochhaus & Liang, 2021).
- Spray-dried insulin formulations with excipients (e.g., mannitol, leucine) are being developed to improve aerodynamic properties and reduce device clogging (Patton et al., 2021).

Table 7: Key Innovations in Inhaled Insulin Formulations.

Innovation	Mechanism	Potential Benefit
Nanoparticle-based formulations	Improved stability and targeted lung delivery	Enhanced bioavailability
Lipid-based carriers	Increased pulmonary absorption	Longer duration of action
Spray-dried microparticles	Optimized aerodynamic properties	Better lung deposition and efficiency
Bioadhesive polymer systems	Prolonged insulin retention in lung tissues	Reduced dosing frequency

Sources: Zhou et al., 2020; Kiparissides et al., 2018; Hochhaus & Liang, 2021; Patton et al., 2021.

6.2 Innovations in Inhaler Device Technology

6.2.1 Smart Inhalers for Precision Dosing

- **Electronic inhalers with Bluetooth connectivity** are being developed to track insulin usage and provide real-time feedback (Clements et al., 2019).
- **AI-based dose adjustments** based on glucose levels could personalize insulin therapy (Sharma et al., 2021).

6.2.2 Miniaturized and Patient-Friendly Devices

- Current inhalation devices (e.g., Afrezza inhaler) are being improved for smaller, more portable designs (Heinemann, 2019).
- Future devices aim for multi-dose reservoirs to reduce refilling frequency (Rosenstock et al., 2015).

6.3 Potential Role in Personalized and AI-Driven Diabetes Management

The integration of artificial intelligence (AI), continuous glucose monitoring (CGM), and digital health tools could transform inhaled insulin therapy.

6.3.1 AI-Driven Insulin Delivery Systems

- AI algorithms could analyze real-time glucose data from CGMs to recommend insulin doses dynamically (Sharma et al., 2021).
- AI-driven predictive modeling could optimize insulin timing based on patient-specific metabolism patterns.

6.3.2 Integration with Digital Health Platforms

- Inhaled insulin could be paired with smartphone apps for dose reminders and adherence tracking (Clements et al., 2019).
- Digital health platforms could offer personalized coaching and lifestyle recommendations based on insulin usage patterns.

6.4 Challenges and Future Research Directions

Despite its potential, several challenges remain in fully integrating inhaled insulin into mainstream diabetes therapy.

6.4.1 Regulatory and Safety Concerns

- Long-term pulmonary safety data is still required to ensure inhaled insulin poses no risks of lung fibrosis or neoplasia (Heinemann, 2019).
- Regulatory agencies like the FDA and EMA continue to monitor the long-term metabolic and respiratory implications of inhaled insulin (Patton et al., 2021).

6.4.2 Cost and Accessibility

- The high cost of inhaled insulin relative to subcutaneous formulations remains a barrier to widespread adoption (Barnett, 2007).
- Future strategies must focus on reducing production costs and improving insurance coverage to enhance accessibility.

6.5 Transforming Diabetes Management: The Road Ahead

If technological, regulatory, and economic barriers are addressed, inhaled insulin could revolutionize diabetes management by:

1. Enhancing patient adherence by eliminating injections.
2. Providing rapid and convenient postprandial glucose control.
3. Reducing hypoglycemia risk due to its shorter action profile.
4. Integrating with AI and digital health for precision diabetes care.

7. Regulatory and Market Landscape

The development of inhalation insulin has been marked by regulatory approvals, setbacks, and relaunches, shaping its market penetration and acceptance in diabetes management. This section provides an overview of FDA approvals, the challenges that led to Exubera's failure, the success of Afrezza, the global availability of inhaled insulin, and the economic aspects such as cost-effectiveness and insurance coverage considerations.

7.1 FDA Approvals, Setbacks, and Relaunches

7.1.1 Regulatory Approvals for Inhalation Insulin

The U.S. Food and Drug Administration (FDA) has been cautious with inhaled insulin products, requiring rigorous evaluation of safety, efficacy, and pulmonary effects before approval. The following milestones highlight the regulatory journey of inhaled insulin:

Exubera (Approved in 2006, Withdrawn in 2007)

- First FDA-approved inhaled insulin product.
- Required pulmonary function testing before prescription due to concerns about lung health (FDA, 2006).
- Withdrawn due to poor market adoption, bulky device design, and financial losses (Barnett, 2007).

Afrezza (Approved in 2014, Currently Available)

- FDA approved Afrezza in 2014 with a requirement for post-marketing safety studies.
- Demonstrated ultra-rapid onset, mimicking physiological insulin response (Heinemann, 2019).
- Initially launched by Sanofi, but after low sales, the partnership ended in 2016, leading to relaunch efforts by MannKind Corporation (Rosenstock et al., 2018).

Ongoing Development of Next-Generation Inhaled Insulin

- Several companies are researching nanoparticle-based and sustained-release inhaled insulin formulations to improve bioavailability and reduce dosage requirements (Brunner et al., 2020).

7.2 Challenges Faced by Exubera and Success of Afrezza

7.2.1 Exubera's Market Failure

Despite high expectations, Exubera failed due to a combination of **clinical, economic, and design-related issues**:

- **Bulky and Complicated Device**
  The **inhaler was large and inconvenient**, reducing patient adherence (Patton et al., 2007).
- **Expensive and Non-Competitive Pricing**
  Exubera was **significantly costlier** than subcutaneous insulin without providing superior efficacy (Skyler et al., 2007).
- **Pulmonary Safety Concerns**
  The requirement for **lung function monitoring (spirometry tests)** discouraged **prescribers and patients** (FDA, 2006).
- **Limited Long-Term Safety Data**

Reports of **lung cancer** in a small number of patients created **public concern**, though causality was never established (Barnett, 2007).

7.2.2 Afrezza's Success and Market Position

Afrezza has demonstrated clinical benefits and better patient adherence due to several improvements over Exubera:

- **Compact, User-Friendly Device (Dreamboat® Inhaler)**
  Smaller and **easier to use**, enhancing patient compliance (Heinemann, 2019).
- **Ultra-Rapid Absorption & Physiological Mimicry**
  Faster onset compared to subcutaneous prandial insulin, making it more effective for postprandial glucose control (Rosenstock et al., 2018).
- **Fewer Pulmonary Safety Concerns**
  While lung function tests are still required, no long-term severe adverse effects have been identified (Patton et al., 2021).
- **Challenges Remain**
  Despite its benefits, Afrezza adoption remains limited due to higher costs and insurance coverage issues (Brunner et al., 2020).

7.3 Global Availability and Market Penetration

7.3.1 United States Market

- Afrezza is FDA-approved and commercially available in the U.S.
- Insurance coverage is variable, affecting prescriber adoption and patient access (B runner et al., 2020).
- Limited availability in hospital and pharmacy formularies reduces prescription rates.

7.3.2 European and Asian Markets

- Exubera was approved in Europe, but its discontinuation limited further adoption.
- Afrezza has yet to receive EMA (European Medicines Agency) approval, restricting its use in Europe (Rosenstock et al., 2018).
- Asian markets remain skeptical due to high cost, lack of local clinical trials, and alternative insulin options.

7.3.3 Future Prospects for Global Expansion

- Companies are developing biosimilar and cost-effective inhaled insulin formulations to increase global reach (Patton et al., 2021).
- Emerging AI-driven smart inhalers could improve patient monitoring and adoption.

7.4 Cost-Effectiveness Analysis and Insurance Coverage Considerations

7.4.1 Cost Comparison with Subcutaneous Insulin

- Afrezza is more expensive than traditional subcutaneous insulin, costing approximately $300–$400 per month compared to $100–$150 for injected insulin (Brunner et al., 2020).
- Price disparities reduce adoption among uninsured and low-income patients.

7.4.2 Insurance and Reimbursement Challenges

- Many insurance companies classify Afrezza as a specialty drug, requiring prior authorization.
- Some plans do not cover Afrezza, forcing patients to pay out-of-pocket (Heinemann, 2019).
- Efforts are being made to include Afrezza in Medicare and Medicaid formularies to expand patient access.

The regulatory and market landscape of inhalation insulin has evolved significantly, with Exubera's failure providing lessons for Afrezza's success. While Afrezza has shown clinical advantages, its cost and insurance challenges limit widespread adoption. Future efforts should focus on cost reduction, global expansion, and integration of smart inhaler technology to improve market penetration and accessibility.

8. Conclusion and Clinical Implications

The introduction of inhaled insulin represents a significant advancement in diabetes management, offering a non-invasive, rapid-acting alternative to traditional subcutaneous insulin injections. This review has explored the mechanism of action, pharmacokinetics, efficacy, safety profile, clinical applications, and future potential of inhaled insulin. While inhaled insulin formulations like Afrezza have demonstrated promising results, their widespread adoption is hindered by cost, long-term pulmonary safety concerns, and regulatory challenges.

8.1 Summary of Key Findings

8.1.1 Clinical Efficacy and Safety

- Inhaled insulin provides faster onset and shorter duration than subcutaneous insulin, improving postprandial glucose control (Rosenstock et al., 2015).
- Studies indicate comparable glycemic control with subcutaneous insulin but with lower risk of hypoglycemia (Heinemann, 2019).
- Long-term pulmonary safety data remain limited, requiring continuous post-market surveillance (Patton et al., 2021).

8.1.2 Patient Adherence and Quality of Life

- The needle-free administration enhances patient compliance, particularly in those with injection anxiety (Clements et al., 2019).
- Despite its advantages, adoption remains low due to cost and insurance limitations (Barnett, 2007).

Table 8: Strengths and Limitations of Inhaled Insulin.

Aspect	Strengths	Limitations
Efficacy	Rapid absorption, better postprandial control	Not suitable for basal insulin needs
Safety	Lower hypoglycemia risk	Long-term pulmonary effects unknown
Convenience	Non-invasive, no injection pain	Requires proper inhalation technique
Patient Adherence	Higher compliance in needle-phobic patients	Expensive compared to subcutaneous insulin
Device	Compact and easy to use	Limited dose flexibility

Sources: Rosenstock et al., 2015; Heinemann, 2019; Clements et al., 2019; Patton et al., 2021.

8.2 Clinical Implications and Future Considerations

8.2.1 Integration into Personalized Diabetes Therapy

- Inhaled insulin can be an effective adjunct to basal insulin regimens, particularly for meal-time glucose control.
- It holds potential for combination therapies with emerging GLP-1 receptor agonists for enhanced glycemic regulation.

8.2.2 Policy and Healthcare System Adoption

- Regulatory authorities (FDA, EMA) should establish long-term monitoring frameworks to ensure safety and efficacy.
- Insurance coverage and pricing reforms are needed to enhance accessibility for a broader patient population.

8.3 The Road Ahead: Transforming Diabetes Care

With advancements in formulation technology, AI-powered dosing systems, and personalized medicine, inhaled insulin is positioned to reshape diabetes management. Continued research, regulatory support, and cost reductions will determine its role in mainstream clinical practice.

REFERENCES

1. American Diabetes Association. Standards of medical care in diabetes—2023. Diabetes Care, 2023; 46(Suppl. 1): S1–S296. https://doi.org/10.2337/dc23-S000
2. Barnett, A. H. Exubera inhaled insulin: A review. Expert Opinion on Pharmacotherapy, 2007; 8(4): 625-632.
3. Bashan, E., et al. Inhaled insulin: Advances in pulmonary drug delivery. Current Diabetes Reports, 2021; 21(3): 45-52.
4. Bode, B. W., McGill, J. B., Lorber, D. L., Gross, J. L., Chang, P. C., & Buse, J. B. Inhaled insulin in patients with type 2 diabetes mellitus inadequately controlled on oral diabetes agents. Diabetes Care, 2015; 38(12): 2266-2273.
5. Brunner, M., et al. Aerosolized insulin delivery: Challenges and future perspectives. Pharmaceutical Research, 2020; 37(2): 120-133.
6. Cefalu, W. T. Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care, 2004; 27(10): 2390-2397.
7. Cefalu, W. T., Dawes, D. E., Gavlak, G., Goldman, D., Herman, W. H., Nuys, K. V., ... & Yatvin, A. L. Insulin access and affordability working group: Conclusions and recommendations. Diabetes Care, 2018; 41(6): 1299-1311. https://doi.org/10.2337/dci18-0019
8. Clements, M. A., Staggs, V. S., & Fedele, D. A. Digital health for diabetes management: Smart inhalers and connected devices. Diabetes Technology & Therapeutics, 2019; 21(5): 211-218.
9. Dunbar, C. A., Hickey, A. J., & Holzner, P. Dispersion and characterization of pharmaceutical dry powder aerosols. KONA Powder and Particle Journal, 2002; 20: 43-52.
10. FDA. (2006). Exubera approval announcement. Food and Drug Administration Reports.
11. Farr, S. J., Patton, J. S., & Byron, P. R. Future of pulmonary drug delivery: Inhaled insulin and beyond. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2021; 34(3): 215-230.
12. Gerich, J. E. Role of insulin resistance in the pathogenesis of type 2 diabetes mellitus. The Mount Sinai Journal of Medicine, 2010; 77(5): 511-523. https://doi.org/10.1002/msj.20212
13. Gross, J. L., Bode, B. W., McGill, J. B., Chang, P. C., & Buse, J. B. Pulmonary insulin delivery: Pharmacokinetics and patient outcomes. Diabetes Care, 2015; 38(12): 2274-2282.
14. Heinemann, L. Alternative insulin delivery routes: Inhaled, transdermal, and implantable pumps. The Lancet Diabetes & Endocrinology, 2019; 7(5): 377-378. https://doi.org/10.1016/S2213-8587(19)30061-6
15. Heinemann, L. The viability of inhaled insulin as a rapid-acting insulin. The Lancet Diabetes & Endocrinology, 2019; 7(5): 377-378.
16. Hochhaus, G., Horhota, S., & Hendrick, A. Inhaled insulin: Clinical pharmacokinetics and metabolism. Clinical Pharmacokinetics, 2015; 54(7): 683-702.
17. Hochhaus, G., & Liang, W. Advances in inhaled insulin formulations and pulmonary drug delivery. Pharmaceutical Research, 2021; 38(1): 22-34.
18. Hood, K. K., Hilliard, M. E., Piatt, G., Ievers-Landis, C. E., & Drotar, D. The psychosocial burden of diabetes: A systematic review. Pediatric Diabetes, 2018; 19(3): 352-366.
19. Kiparissides, C., Koutsiaris, A. G., & Demetzos, C. Advances in pulmonary drug delivery using nanoparticle-based carriers. Journal of Drug Delivery Science and Technology, 2018; 44: 165-178.
20. Liang, W., & Hochhaus, G. Advances in inhaled insulin formulations. Pharmaceutical Research, 2021; 38(1): 22-34.

21. McGill, J. B., Bode, B. W., Lorber, D. L., Gross, J. L., Chang, P. C., & Buse, J. B. Inhaled insulin in patients with type 2 diabetes mellitus inadequately controlled on oral diabetes agents. Diabetes Care, 2015; 38(12): 2266-227.
22. Owens, D. R., Zinman, B., & Bolli, G. B. Insulins today and beyond. The Lancet, 2001; 358(9283): 739-746. https://doi.org/10.1016/S0140-6736(01)05520-1
23. Patton, J. S., & Byron, P. R. Inhaling medicines: Delivering drugs to the body through the lungs. Nature Reviews Drug Discovery, 2007; 6(1): 67-74. https://doi.org/10.1038/nrd2153
24. Patton, J. S., Byron, P. R., & Farr, S. J. Future of pulmonary drug delivery: Inhaled insulin and beyond. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2021; 34(3): 215-230.
25. Polonsky, W. H., & Henry, R. R. Poor medication adherence in type 2 diabetes: Recognizing the scope of the problem and its key contributors. Diabetes Spectrum, 2016; 29(3): 170-175.
26. Qiao, J., Sun, X., & Zhang, Z. Advances in nanoparticle-based pulmonary insulin delivery. Advanced Drug Delivery Reviews, 2020; 166: 54-72.
27. Rosenstock, J., et al. Inhaled insulin: An updated review. Diabetes Technology & Therapeutics, 2015; 17(2): 99-115.
28. Rosenstock, J., et al. Inhaled insulin therapy: Future perspectives. Diabetes Technology & Therapeutics, 2018; 20(9): 667-679.
29. Sharma, A., Chakraborty, C., & Kim, T. AI-powered digital health platforms for insulin therapy: The next frontier. Artificial Intelligence in Medicine, 2021; 123: 102193.
30. Skyler, J. S. Insulin therapy in type 2 diabetes mellitus: Strategies for initiation and long-term patient adherence. The American Journal of Medicine, 2004; 116(5): 3S-9S. https://doi.org/10.1016/j.amjmed.2003.10.009
31. Skyler, J. S., Weinstock, R. S., Raskin, P., & Yale, J. F. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetes. Annals of Internal Medicine, 2005; 143(8): 549-558.
32. Westly, E. Pfizer withdraws inhaled insulin Exubera. Nature Biotechnology, 2006; 25(12): 1331-1332. https://doi.org/10.1038/nbt1207-1331
33. Zhou, Q., Sun, X., & Zhang, Z. Advances in nanoparticle-based pulmonary insulin delivery. Advanced Drug Delivery Reviews, 2020; 166: 54-72.